Adial Pharmaceuticals Advances Toward Phase 3 Development for AD04

Stock Information for Galectin Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Galectin Therapeutics Inc.

Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds
Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show
Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution
Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments
Adial Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.